BioSpace News Archive

Electromed, Inc. today announced that Jim Cunniff, President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer, are scheduled to attend the 2024 Sidoti March Small-Cap Virtual Conference on March 13-14, 2024.

Blue Earth Therapeutics today announced that it will be presenting at the upcoming B. Riley Securities’ Radiopharma Investor Conference. The event will be held in New York, N.Y., on March 1, 2024.

Scilex Holding Company announced a major initiative with a leading national pharmacy chain to stock GLOPERBA® in most of their stores throughout the U.S. GLOPERBA®, an FDA-approved prophylactic treatment for painful gout flares in adults in the U.S., is expected to launch in the U.S. in first half of 2024.

BlueWind Medical, Ltd. today announced that Dr. Osvaldo Padron of Florida Urology Partners in Tampa, Florida, has treated the first patient in the RESTORE study, a prospective, multi-center, open label, post market, randomized controlled trial.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced patent number 11,905,562 was issued on February 20, 2024 by the United States Patent and Trademark Office.

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.

Innovation for patients suffering from angina due to persistent ischemic heart disease

BioMark Diagnostics Inc, an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, and Rubix LS, a culturally competent patient medical research organization, jointly announce today the signature of a strategic partnership

Autonomous Medical Devices Incorporated has received a National Institutes of Health RADx Tech award from the National Institute of Biomedical Imaging and Bioengineering, part of the NIH.

IGC Pharma, Inc. announced the results of preclinical studies investigating its drug candidate TGR-63 as a treatment for Alzheimer’s disease.